Overview

* Adicet Bio ( ACET ) reports Q2 net loss of $31.2 mln, $0.34 per share

* R&D expenses rise to $28.4 mln, G&A expenses decrease to $6.9 mln

* Company reduces workforce by 30% to extend cash runway to Q4 2026

Outlook

* Adicet expects preliminary ADI-001 data in 2H/2025

* Company plans regulatory filing for ADI-212 in Q1/2026

* Adicet anticipates initial ADI-212 data in 2H/2026

* Company expects cash runway into Q4/2026

Result Driver

* PIPELINE PRIORITIZATION - Strategic review led to discontinuation of ADI-270 and 30% workforce reduction to extend cash runway

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Net -$31.22

Income mln

Q2 Basic -$0.34

EPS

Q2 $32.39

Operatin mln

g

Expenses

Q2 -$32.39

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Adicet Bio Inc ( ACET ) is $6.00, about 88.3% above its August 6 closing price of $0.70

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)